Metriopharm
  • en
  • de
MetrioPharm AG
  • Home
  • About us
    • Our Company
    • Management and Board
    • Career
  • Technology
    • MetrioPharm Platform
    • Mechanism of Action
    • Scientific Publications
  • Pipeline
    • Indications
    • Patent Protection
  • Investors
    • IR-News
    • Financial Reports and Downloads
    • Annual General Meeting
  • Press
    • Press Releases
    • Corporate Calendar
  • Contact
    • Contact form
    • Privacy policy
    • Imprint
  • en
  • de
  1. Home
  2. About us
  3. Sitemap

Sitemap

Get a quick overview:
We provide you a sitemap, which shows the structure of our website in a simple form.

 
  • Home
  • About us
    • Our Company
    • Management and Board
    • Career
  • Technology
    • MetrioPharm Platform
    • Mechanism of Action
    • Scientific Publications
  • Pipeline
    • Indications
    • Patent Protection
  • Investors
    • IR-News
    • Financial Reports and Downloads
    • Annual General Meeting
  • Press
    • Press Releases
    • Corporate Calendar
  • Contact
    • Contact form
    • Privacy policy
    • Imprint
 

News

MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients - 2022-Dec-08

MP1032 has many advantages over other available antivirals: it can be conveniently administered orally and has both anti-inflammatory and anti-Sars-CoV-2 properties, making it an ideal candidate to prevent a so-called cytokine storm. 

» more

Investor Relations

Investor Relations News QIV 2022 - 2022-Dec-22

Holiday Greetings from CEO Thomas Christély

» more

Blog

Read our latest blog post: - 2021-May-12

Phase II Clinical Trial in COVID-19

» more

Navigation

  • Home
  • About us
  • Technology
  • Pipeline
  • Investors
  • Press
  • Contact

Social

        

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Europaallee 41
8004 Zurich

Phone: +41 44 552 7190

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 30 3384 395 02

  • © 2023 MetrioPharm AG
  • Imprint
  • Privacy policy (We don’t collect cookies)
  • Sitemap